Research & Development

Vividion Therapeutics to expand capabilities with new R&D centre in US

Vividion Therapeutics has announced plans to broaden its capabilities with the establishment of a new research and development (R&D) centre and corporate headquarters at San Diego in California, US.

Lynch Regenerative Medicine secures funds to develop skin regeneration solutions

Lynch Regenerative Medicine (LRM) has closed its Series A financing round for the development and commercialisation of advanced skin rejuvenation and regeneration solutions.

Merck enhances ophthalmology portfolio with EyeBio acquisition

MSD (Merck & Co) has completed the acquisition of EyeBio, making it a wholly-owned subsidiary, and bolstering its ophthalmology portfolio.

Juniper to distribute Caris Life Sciences’ molecular profiling services in MEA

Singapore-based Juniper Biologics has secured the distribution rights for Caris Life Sciences' advanced solid tumour molecular profiling services in the Middle East and Africa (MEA).

DoH expands research partnership with Penn Medicine

The Department of Health – Abu Dhabi (DoH) and the Perelman School of Medicine at the University of Pennsylvania (Penn Medicine) have signed a second Memorandum of Understanding (MoU) to broaden their collaboration in translational research.

Telix seeks BLA for TLX250-CDx aimed at kidney cancer imaging

Telix Pharmaceuticals has completed Biologics License Application (BLA) submission to the US Food and Drug Administration (FDA) for TLX250-CDx (Zircaix), a radiodiagnostic agent for identifying clear cell renal cell carcinoma (ccRCC) in kidney cancer patients.

FogPharma and ARTBIO collaborate to co-develop new cancer therapies

FogPharma has partnered with ARTBIO to co-develop Helicon-enabled alpha radioligand therapies (HEARTs), a new class of treatments aimed at improving outcomes for cancer patients.

PharmaLogic launches new radiopharmaceutical facility in New York, US

PharmaLogic, a contract development and manufacturing organization (CDMO) and provider of radiopharmacy solutions, has announced the launch of its new radiopharmaceutical manufacturing and research facility at the Bronx in New York city, US.

Latus Bio secures $54m for CNS gene therapy development

Latus Bio, a biotechnology company specialising in new gene therapy candidates for central nervous system (CNS) disorders, has announced its launch alongside an initial $54m Series A financing.